Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 4/20 | 0.58 |
| ▸ | DHFR | P00374 | 3/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024471 | 0.82 | PIK3CD (0.66) | TP53MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL4017562 | 0.80 | PIK3CA (0.42) | ABCG2TP53MAPTSMN1; SMN2PIK3CA | |
| SCHEMBL2300591 | 0.78 | PIK3CD (0.72) | MAPTPIK3CAALDH1A1MEN1KMT2A | |
| SCHEMBL4018007 | 0.77 | TYMS (0.59) | TYMSDHFRTP53MAPTSMN1; SMN2 | |
| SCHEMBL4020733 | 0.77 | TYMS (0.59) | TYMSDHFRABCG2TP53MAPT | |
| SCHEMBL4019255 | 0.76 | TYMS (0.61) | TYMSDHFRTP53MAPTSMN1; SMN2 | |
| SCHEMBL12055729 | 0.76 | PIK3CD (0.43) | TYMSDHFRABCG2TP53MAPT | |
| SCHEMBL2301415 | 0.75 | PIK3CG (0.53) | MAPTSMN1; SMN2PIK3CAKDM4EALDH1A1 | |
| SCHEMBL4019248 | 0.75 | TYMS (0.57) | TYMSDHFRABCG2TP53MAPT | |
| SCHEMBL4026477 | 0.73 | TYMS (0.55) | TYMSDHFRABCG2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-29 | — | — | US | disclosed |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | MERCK SERONO SA (CH) | 2011-12-22 | — | — | US | disclosed |
| US-8071597-B2 | Pyrazine compounds and uses as PI3K inhibitors | MERCK SERONO SA (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | PI4KA, PIP5K1B, PDPK1 | TYMS 1605/4885DHFR 4026/4885ABCG2 3857/4885 |
| US-20110312960-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | TYMS 822/4885DHFR 3763/4885ABCG2 3576/4885 |
| US-20110319410-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | PIK3R5, PIK3CD, PIK3CA | TYMS 822/4885DHFR 3763/4885ABCG2 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.